	Application No.	Applicant(s)
Notice of Allowability	10/010,644	DAI, YIFAN
	Examiner	Art Unit
	Joseph T. Woitach	1632
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>8/20/2004</u> .		
2. The allowed claim(s) is/are 10-17.		
3. The drawings filed on <u>08 November 2001</u> are accepted by the Examiner.		
<ul> <li>4.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a)  All b)  Some* c)  None of the:</li> <li>1.  Certified copies of the priority documents have been received.</li> <li>2.  Certified copies of the priority documents have been received in Application No</li> <li>3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* Certified copies not received:</li> </ul>		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
<ul> <li>6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.</li> <li>(a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached</li> <li>1) hereto or 2) to Paper No./Mail Date</li> <li>(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date</li> <li>Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).</li> <li>7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.</li> </ul>		
Attachment(s)  1. Notice of References Cited (PTO-892)  2. Notice of Draftperson's Patent Drawing Review (PTO-948)  3. Information Disclosure Statements (PTO-1449 or PTO/SB/O Paper No./Mail Date  4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Summa Paper No./Mail [ 98), 7. ☑ Examiner's Amer	Date

Application/Control Number: 10/010,644

Art Unit: 1632

## **DETAILED ACTION**

This application filed November 8, 2001, is a continuation of application 08/789,886, filed January 28, 1997, now abandoned.

Applicant's amendment filed August 20, 2004, has been received and entered. Claim 10 has been amended. Claims 11-17 have been added. Claims 10-17 are pending.

## Election/Restrictions

Newly added claims 11-17 are dependent on claim 10, and are encompassed by the elected invention. Claims 10-17 are pending and currently under examination.

## Reasons for Allowance

The following is an examiner's statement of reasons for allowance:

The claims have been amended to differentiate the claimed invention from that disclosed in the prior art. As acknowledged in the specification, methods of using adenoviral shuttle vectors, plasmids and helper cells were known and used in the art at the time of filing. The instantly claimed invention is differentiated from the methods known in the art at the time filing in that the shuttle vector and plasmid is heated to 35°-70° before it is transfected into the host helper cell. The specification teaches that this provides a better recombination between the vector and the plasmid. The prior art fails to teach or provide motivation for heating the composition containing the shuttle vector and plasmid before transfection. While the prior art teaches that heating was used to inactivate wild type viral particles in a preparation in

Application/Control Number: 10/010,644

Art Unit: 1632

purification or inactivation protocols, there is no specific teaching to heat the composition of a plasmid and vector.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Woitach whose telephone number is (571) 272-0739.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached at (571) 272-0734.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group analyst Dianiece Jacobs whose telephone number is (571) 272-0532.

Joseph T. Woitach

PART DELLE

Ja Worton